Bristol Myers Squibb (CELG-RI) Finished Goods (2010 - 2013)
Bristol Myers Squibb (CELG-RI) reported Finished Goods of $569.0 million for Q1 2013, up 13.57% year-over-year from $501.0 million in Q1 2012, and down 0.52% quarter-over-quarter from $572.0 million in Q4 2012.
Bristol Myers Squibb (CELG-RI) Finished Goods (2010 - 2013) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has 4 years of Finished Goods data on file, last reported at $569.0 million in Q1 2013.
- Finished Goods for Q1 2013 came in at $569.0 million, up 13.57% year-over-year; the trailing twelve-month figure through Mar 2013 was $569.0 million (up 13.57% YoY), and the FY2012 annual result was $572.0 million, up 19.67% from the prior year.
- Finished Goods eased to $569.0 million in Q1 2013 per CELG-RI's latest filing, from $572.0 million in the prior quarter.
- Over five years, Finished Goods peaked at $572.0 million in Q4 2012 and troughed at $397.0 million in Q4 2010.
- A 4-year average of $484.7 million and a median of $489.5 million in 2011 frame the typical range for Finished Goods.
- The sharpest annual moves came in 2012 and 2013: Finished Goods rose 21.01% in 2012, then increased 13.57% in 2013.
- A 4-year view of Finished Goods shows it stood at $397.0 million in 2010, then increased by 20.4% to $478.0 million in 2011, then advanced by 19.67% to $572.0 million in 2012, then decreased by 0.52% to $569.0 million in 2013.
- Business Quant data shows CELG-RI's Finished Goods at $569.0 million in Q1 2013, $572.0 million in Q4 2012, and $533.0 million in Q3 2012.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn |
| 10 | Bristol Myers Squibb | - | - | 8.07 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2013 | 569.00 Mn |
| Dec 31, 2012 | 572.00 Mn |
| Sep 30, 2012 | 533.00 Mn |
| Jun 30, 2012 | 503.00 Mn |
| Mar 31, 2012 | 501.00 Mn |
| Dec 31, 2011 | 478.00 Mn |
| Sep 30, 2011 | 443.00 Mn |
| Jun 30, 2011 | 437.00 Mn |
| Mar 31, 2011 | 414.00 Mn |
| Dec 31, 2010 | 397.00 Mn |